Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-2626
Abstract: Purpose: PR1 is a human leukocyte antigen (HLA)-A2 nonameric peptide derived from neutrophil elastase (NE) and proteinase 3 (P3). We have previously shown that PR1 is cross-presented by solid tumors, leukemia, and antigen-presenting cells, including… read more here.
Keywords: multiple myeloma; cross; leukemia antigen; pr1 ... See more keywords